$NBIX News

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript

Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213

Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?

Neurocrine Biosciences Q2 Earnings Call Highlights

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $249

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198

NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth

Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $196

TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $210

Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $222

Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215

Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $204

Neurocrine Biosciences Inc (NBIX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript